Clinical trial

Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer

NCT06495515

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-08-01

PhasePHASE2

Study timeline

Study start (actual)2024-08-01Date precision: day

Registry last updated2026-09-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

CANCERunresolved

BRAEST CANCERunresolved

Late Frontlineunresolved

Interventions

Dalpiciclib，ToremifenDRUG

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06495515 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.